Adler LA, Adams J, Madera-McDonough J, Kohegyi E, Hobart M, Chang D, Angelicola M, McQuade R, Liebowitz M (2022) Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol 42:429–439. https://doi.org/10.1097/JCP.0000000000001575

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anighoro A, Bajorath J, Rastelli G (2014) Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 57:7874–7887. https://doi.org/10.1021/jm5006463

Article  PubMed  CAS  Google Scholar 

Appel L, Bergström M, Buus Lassen J, Långström B (2014) Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol 24:251–261. https://doi.org/10.1016/j.euroneuro.2013.10.007

Article  PubMed  CAS  Google Scholar 

Arakawa R, Stenkrona P, Takano A, Svensson J, Andersson M, Nag S, Asami Y, Hirano Y, Halldin C, Lundberg J (2019) Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: a PET study using [18F]FMeNER-D2. Int J Neuropsychopharmacol 22:278–285. https://doi.org/10.1093/ijnp/pyz003

Article  PubMed  PubMed Central  CAS  Google Scholar 

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM (2008) Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372:1906–1913. https://doi.org/10.1016/S0140-6736(08)61525-1

Article  PubMed  CAS  Google Scholar 

BayatMokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8:38022–43. https://doi.org/10.18632/oncotarget.16723

Article  Google Scholar 

Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, Khan A, Weisler R, Nelson C, Shelton R, Thase ME, Lane R (2015) Assessment of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression: results from 2 randomized, double-blind studies. J Clin Psychopharmacol 35:454–459. https://doi.org/10.1097/JCP.0000000000000335

Article  PubMed  CAS  Google Scholar 

Buckhout R, Grace T (1966) The effect of food deprivation and expectancy on heart rate. Psychonomic Science 6:153–154. https://doi.org/10.3758/BF03328003

Article  Google Scholar 

Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JC, Guilloteau D (1999) Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4’-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291:648–654

PubMed  CAS  Google Scholar 

Chalon S, Tarkiainen J, Garreau L, Hall H, Emond P, Vercouillie J, Farde L, Dasse P, Varnas K, Besnard JC, Halldin C, Guilloteau D (2003) Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. J Pharmacol Exp Ther 304:81–87. https://doi.org/10.1124/jpet.102.042226

Article  PubMed  CAS  Google Scholar 

Chen X, Kudo T, Lapa C, Buck A, Higuchi T (2020) Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements. J Neural Transm (Vienna) 127:851–873. https://doi.org/10.1007/s00702-020-02180-4

Article  PubMed  Google Scholar 

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika S, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391:1357–1366. https://doi.org/10.1176/appi.focus.16407

Article  PubMed  PubMed Central  CAS  Google Scholar 

Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, Shotbolt P, Van der Aart J, Neve M, Iavarone L, Gomeni R, Laruelle M, Gray FA, Gunn RN, Rabiner EA (2013) Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther 346:311–317. https://doi.org/10.1124/jpet.112.202895

Article  PubMed  CAS  Google Scholar 

Culpepper L, Muskin PR, Stahl SM (2015) Major depressive disorder: understanding the significance of residual symptoms and balancing efficacy with tolerability. Am J Med 128:S1–S15. https://doi.org/10.1016/j.amjmed.2015.07.001

Article  PubMed  Google Scholar 

Cuss F (2015) Francis c Cuss. Nat Rev Drug Discovery 14:672–673. https://doi.org/10.1038/nrd4748

Deest M, Jakob MM, Seifert J, Bleich S, Frieling H, Eberlein C (2021) Sertraline as a treatment option for temper outbursts in Prader-Willi syndrome. Am J Med Genet A 185:790–797. https://doi.org/10.1002/ajmg.a.62041

Article  PubMed  CAS  Google Scholar 

DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV (2011) SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med 52:1150–1155. https://doi.org/10.2967/jnumed.110.084525

Article  PubMed  Google Scholar 

Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, Frangin Y, Mauclaire L, Besnard JC, Guilloteau D (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4’-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3’,4’-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 40:1366–1372. https://doi.org/10.1021/jm960795d

Article  PubMed  CAS  Google Scholar 

Fava M, Rush AJ (2006) Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 75:139–153. https://doi.org/10.1159/000091771

Article  PubMed  Google Scholar 

Guilloteau D, Emond P, Baulieu JL, Garreau L, Frangin Y, Pourcelot L, Mauclaire L, Besnard JC, Chalon S (1998) Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4’-m ethylph enyl)nortropane (PE2I). Nucl Med Biol 25:331–337. https://doi.org/10.1016/s0969-8051(97)00224-2

Article  PubMed  CAS  Google Scholar 

Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G (1999) Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage 9:108–116. https://doi.org/10.1006/nimg.1998.0366

Article  PubMed  CAS  Google Scholar 

Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L (2003) [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30:1220–1230. https://doi.org/10.1007/s00259-003-1212-3

Article  PubMed  CAS  Google Scholar 

Halldin C, Lundberg J, Sovago J, Gulyas B, Guilloteau D, Vercouillie J, Emond P, Chalon S, Tarkiainen J, Hiltunen J, Farde L (2005) [(11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 58:173–183. https://doi.org/10.1002/syn.20189

Article  PubMed  CAS  Google Scholar 

Hirvonen J, Johansson J, Teras M, Oikonen V, Lumme V, Virsu P, Roivainen A, Nagren K, Halldin C, Farde L, Hietala J (2008) Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 28:1059–1069. https://doi.org/10.1038/sj.jcbfm.9600607

Article  PubMed  CAS  Google Scholar 

Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U (2022) Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol 186:687–700. https://doi.org/10.1530/EJE-21-0972

Article  PubMed  PubMed Central  CAS  Google Scholar 

James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, Investigators S (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905–917. https://doi.org/10.1056/NEJMoa1003114

Article  PubMed  CAS  Google Scholar 

Jovanovic H, Lundberg J, Karlsson P, Cerin A, Saijo T, Varrone A, Halldin C, Nordström AL (2008) Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 39(3):1408–1419. https://doi.org/10.1016/j.neuroimage.2007.10.016

Article  PubMed